

anzdata@anzdata.org.au

**ANZ  
DATA**

AUSTRALIA &  
NEW ZEALAND  
DIALYSIS & TRANSPLANT  
REGISTRY



# MISSING DATA REPORT

Survey Data 2016 – 2020

[Abstract](#)

The rates of non-response for ANZDATA survey items over the last 5 years.  
The tables shown here present the rates of non-response for ANZDATA survey items over the last 5 years, as N (%).

# ANZDATA Missing Data Report

The tables below show the rates of non-response for ANZDATA survey items over the last 5 years, as N (%). The first row (Frequency) shows the number of patients that should have a response for the item. As rates of non-response have increased in recent years, individual hospital missing data reports will also be produced and supplied to units to highlight areas where reporting should improve. Rates can appear higher in the latest survey year as not all survey queries are received by the date of data lock.

## Contents

Table 1 Demographics .....	4
Table 2 Comorbidities at RRT entry.....	4
Table 3 Comorbidities at survey date .....	4
Table 4 Reason for change from CAPD to APD .....	5
Table 5 Reason for change from APD to CAPD .....	5
Table 6 Reason for change from PD to HD .....	5
Table 7 Reason for change from HD to PD .....	5
Table 8 Cause of death.....	5
Table 9 Dialysis data.....	5
Table 10 Haemodialysis data.....	6
Table 11 Access at first HD.....	6
Table 12 Peritoneal dialysis data .....	6
Table 13 Peritoneal dialysis PET test .....	6
Table 14 Peritonitis episodes data.....	7
Table 15 Transplant baseline data.....	7
Table 16 Cause of graft failure.....	7
Table 17 Rejection data .....	8
Table 18 Rejection data if biopsy performed .....	8
Table 19 Rejection data if biopsy not performed .....	8
Table 20 Transplant follow-up data, 0 months.....	9
Table 21 Transplant follow-up data, 1 months.....	9
Table 22 Transplant follow-up data, 2 months.....	9

# ANZDATA Missing Data Report

---

Table 23 Transplant follow-up data, 3 months.....	9
Table 24 Transplant follow-up data, 6 months.....	9
Table 25 Transplant follow-up data, 12 months.....	9
Table 26 Transplant follow-up data, 24 months.....	10
Table 27 Transplant follow-up data, 36 months.....	10
Table 28 Transplant follow-up data, 60 months.....	10
Table 29 Transplant follow-up data, 84 months.....	10
Table 30 Transplant follow-up data, 120 months.....	10
Table 31 Transplant follow-up data, 180 months.....	10
Table 32 Transplant follow-up data, 240 months.....	11
Table 33 Transplant follow-up data, 300 months.....	11
Table 34 Transplant follow-up data, 360 months.....	11
Table 35 Transplant follow-up data, 420 months.....	11
Table 36 Transplant follow-up data, 480 months.....	11
Table 37 Transplant follow-up data, 540 months.....	11
Table 38 Transplant follow-up data, 600 months.....	12
Table 39 Paediatric assessment at entry.....	12
Table 40 Paediatric assessment at survey.....	12
Table 41 Parenthood data.....	12
Table 42 Parenthood birthweight data.....	13
Table 43 Parenthood creatinine prior to conception.....	13
Table 44 Parenthood creatinine post delivery.....	13
Table 45 Non-skin cancer data.....	13

# ANZDATA Missing Data Report



**Table 1 Demographics**

Variable	2016	2017	2018	2019	2020
Frequency	3533	3769	3830	3934	3971
Date of birth	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gender	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Country of birth	107 (3.0%)	50 (1.3%)	67 (1.7%)	29 (0.7%)	11 (0.3%)
Late referral seen <3 mths before 1st treatment	157 (4.4%)	75 (2.0%)	90 (2.3%)	54 (1.4%)	54 (1.4%)
Ethnicity 1	122 (3.5%)	50 (1.3%)	80 (2.1%)	47 (1.2%)	57 (1.4%)
Primary renal disease	102 (2.9%)	56 (1.5%)	75 (2.0%)	27 (0.7%)	42 (1.1%)
Was native kidney biopsied?	231 (6.5%)	107 (2.8%)	101 (2.6%)	115 (2.9%)	64 (1.6%)
Serum creatinine at entry	144 (4.1%)	92 (2.4%)	99 (2.6%)	69 (1.8%)	59 (1.5%)
Height at RRT entry (cm)	187 (5.3%)	123 (3.3%)	111 (2.9%)	180 (4.6%)	80 (2.0%)
Weight at RRT entry (kg)	129 (3.7%)	67 (1.8%)	61 (1.6%)	93 (2.4%)	30 (0.8%)
Smoking status at RRT entry	172 (4.9%)	110 (2.9%)	101 (2.6%)	115 (2.9%)	59 (1.5%)

**Table 2 Comorbidities at RRT entry**

Variable	2016	2017	2018	2019	2020
Frequency	3533	3769	3830	3934	3971
Postcode	160 (4.5%)	60 (1.6%)	74 (1.9%)	56 (1.4%)	25 (0.6%)
Chronic lung disease	54 (1.5%)	30 (0.8%)	22 (0.6%)	80 (2.0%)	43 (1.1%)
Coronary artery disease	57 (1.6%)	30 (0.8%)	22 (0.6%)	79 (2.0%)	43 (1.1%)
Peripheral vascular disease	55 (1.6%)	30 (0.8%)	22 (0.6%)	78 (2.0%)	42 (1.1%)
Cerebrovascular disease	56 (1.6%)	29 (0.8%)	22 (0.6%)	79 (2.0%)	44 (1.1%)
Diabetes	54 (1.5%)	24 (0.6%)	26 (0.7%)	43 (1.1%)	39 (1.0%)

**Table 3 Comorbidities at survey date**

Variable	2016	2017	2018	2019	2020
Frequency	32004	33266	34440	35705	36922
Postcode	1193 (3.7%)	407 (1.2%)	498 (1.4%)	393 (1.1%)	120 (0.3%)
Chronic lung disease	151 (0.5%)	133 (0.4%)	98 (0.3%)	151 (0.4%)	155 (0.4%)
Coronary artery disease	154 (0.5%)	131 (0.4%)	98 (0.3%)	150 (0.4%)	155 (0.4%)
Peripheral vascular disease	152 (0.5%)	131 (0.4%)	98 (0.3%)	149 (0.4%)	154 (0.4%)
Cerebrovascular disease	156 (0.5%)	133 (0.4%)	100 (0.3%)	152 (0.4%)	158 (0.4%)
Diabetes	157 (0.5%)	121 (0.4%)	99 (0.3%)	119 (0.3%)	129 (0.3%)
Hepatitis C Antibody	241 (0.8%)	192 (0.6%)	231 (0.7%)	246 (0.7%)	229 (0.6%)

# ANZDATA Missing Data Report



**Table 4 Reason for change from CAPD to APD**

Variable	2016	2017	2018	2019	2020
Frequency	611	623	643	651	605
Reason transfer from dialysis during survey	54 (8.8%)	33 (5.3%)	23 (3.6%)	70 (10.8%)	42 (6.9%)

**Table 5 Reason for change from APD to CAPD**

Variable	2016	2017	2018	2019	2020
Frequency	118	142	83	110	101
Reason transfer from dialysis during survey	16 (13.6%)	18 (12.7%)	4 (4.8%)	14 (12.7%)	15 (14.9%)

**Table 6 Reason for change from PD to HD**

Variable	2016	2017	2018	2019	2020
Frequency	839	810	810	797	831
Reason transfer from dialysis during survey	90 (10.7%)	51 (6.3%)	35 (4.3%)	66 (8.3%)	50 (6.0%)

**Table 7 Reason for change from HD to PD**

Variable	2016	2017	2018	2019	2020
Frequency	539	553	525	526	514
Reason transfer from dialysis during survey	66 (12.2%)	31 (5.6%)	18 (3.4%)	21 (4.0%)	32 (6.2%)

**Table 8 Cause of death**

Variable	2016	2017	2018	2019	2020
Frequency	2560	2697	2618	2738	2658
Cause of death	22 (0.9%)	107 (4.0%)	65 (2.5%)	64 (2.3%)	57 (2.1%)

**Table 9 Dialysis data**

Variable	2016	2017	2018	2019	2020
Frequency	19047	19528	19928	20474	20968
Dialysis type	258 (1.4%)	191 (1.0%)	820 (4.1%)	901 (4.4%)	953 (4.5%)
Dry Weight on last dialysis: End Survey, Transplantation or Death	1697 (8.9%)	985 (5.0%)	867 (4.4%)	948 (4.6%)	1065 (5.1%)
Uncorrected calcium levels (mmol/l)	1569 (8.2%)	917 (4.7%)	847 (4.3%)	1078 (5.3%)	1343 (6.4%)
Phosphate levels (mmol/l)	1541 (8.1%)	898 (4.6%)	819 (4.1%)	1080 (5.3%)	1317 (6.3%)
Haemoglobin level nearest end Survey (g/l)	1536 (8.1%)	913 (4.7%)	820 (4.1%)	1069 (5.2%)	1303 (6.2%)
EPO Agent	1569 (8.2%)	925 (4.7%)	817 (4.1%)	997 (4.9%)	1146 (5.5%)
Ferritin within last 3 months of Survey	2704 (14.2%)	2026 (10.4%)	1916 (9.6%)	1981 (9.7%)	2485 (11.9%)
% Saturation Iron (Transferrin Saturation) within last 3 months of survey	3338 (17.5%)	2413 (12.4%)	2502 (12.6%)	2676 (13.1%)	2842 (13.6%)

# ANZDATA Missing Data Report

**Table 10 Haemodialysis data**

Variable	2016	2017	2018	2019	2020
Frequency	15395	15851	16259	16850	17288
Dialyser brand, model, membrane, surface area	1106 (7.2%)	816 (5.1%)	719 (4.4%)	964 (5.7%)	795 (4.6%)
Blood flow rate (mls/min)	1374 (8.9%)	815 (5.1%)	727 (4.5%)	964 (5.7%)	809 (4.7%)
Frequency of dialysis per week	1348 (8.8%)	789 (5.0%)	691 (4.2%)	936 (5.6%)	780 (4.5%)
Hours per session	1368 (8.9%)	813 (5.1%)	719 (4.4%)	953 (5.7%)	795 (4.6%)
Adequacy method (urea reduction or Kt/V)	3559 (23.1%)	2991 (18.9%)	3005 (18.5%)	3572 (21.2%)	3064 (17.7%)
Adequacy value (Urea reduction ratio % or Kt/V value on HD)	3447 (22.4%)	3012 (19.0%)	3005 (18.5%)	3572 (21.2%)	3064 (17.7%)
Vascular access in use at last haemodialysis	1411 (9.2%)	835 (5.3%)	739 (4.5%)	1006 (6.0%)	830 (4.8%)

**Table 11 Access at first HD**

Variable	2016	2017	2018	2019	2020
Frequency	2910	3113	3168	3322	3238
Vascular access in use at first haemodialysis	229 (7.9%)	113 (3.6%)	92 (2.9%)	146 (4.4%)	105 (3.2%)

**Table 12 Peritoneal dialysis data**

Variable	2016	2017	2018	2019	2020
Frequency	4794	4794	4778	4723	4831
Type of Peritoneal Connection System	419 (8.7%)	257 (5.4%)	194 (4.1%)	248 (5.3%)	301 (6.2%)
Total volume weekly exchanges - All PD	577 (12.0%)	252 (5.3%)	174 (3.6%)	321 (6.8%)	320 (6.6%)
PD Solution Glucose	453 (9.4%)	249 (5.2%)	162 (3.4%)	262 (5.5%)	310 (6.4%)
PD Solution Iodextrin	451 (9.4%)	250 (5.2%)	162 (3.4%)	276 (5.8%)	311 (6.4%)
PD Solution Low GDP (either Lactate or Bicarbonate)	452 (9.4%)	246 (5.1%)	164 (3.4%)	264 (5.6%)	315 (6.5%)
Creatinine Clearance (litres per week)	1803 (37.6%)	1581 (33.0%)	1471 (30.8%)	1641 (34.7%)	1961 (40.6%)
Dialysate Only Weekly Kt/V value on PD	1803 (37.6%)	1571 (32.8%)	1480 (31.0%)	1633 (34.6%)	1958 (40.5%)
Residual renal function (creatinine clearance - GFR)	1837 (38.3%)	1615 (33.7%)	1490 (31.2%)	1656 (35.1%)	1968 (40.7%)

**Table 13 Peritoneal dialysis PET test**

Variable	2016	2017	2018	2019	2020
Frequency	1394	1408	1393	1359	1516
PET test for PD-within first 6 mths starting?	1327 (95.2%)	1319 (93.7%)	1258 (90.3%)	969 (71.3%)	984 (64.9%)

# ANZDATA Missing Data Report

**Table 14 Peritonitis episodes data**

Variable	2016	2017	2018	2019	2020
Frequency	1105	1088	1140	971	903
Was this a relapse or recurrence of peritonitis?	152 (13.8%)	141 (13.0%)	107 (9.4%)	119 (12.3%)	16 (1.8%)
Technique at time of infection	46 (4.2%)	32 (2.9%)	31 (2.7%)	68 (7.0%)	6 (0.7%)
Antifungal Therapy?	184 (16.7%)	170 (15.6%)	109 (9.6%)	178 (18.3%)	46 (5.1%)
Name of initial regimen first antibiotic given	145 (13.1%)	142 (13.1%)	101 (8.9%)	118 (12.2%)	25 (2.8%)
Name of final regimen first antibiotic given	170 (15.4%)	159 (14.6%)	127 (11.1%)	157 (16.2%)	95 (10.5%)
Glucose PD Solution at time of infection?	203 (18.4%)	189 (17.4%)	145 (12.7%)	148 (15.2%)	51 (5.6%)
Icodextrin PD Solution at time of infection?	214 (19.4%)	191 (17.6%)	145 (12.7%)	150 (15.4%)	56 (6.2%)
Low GDP PD Solution (either Lactate or Bicarbonate) at time of infection?	200 (18.1%)	208 (19.1%)	165 (14.5%)	152 (15.7%)	56 (6.2%)
Was patient hospitalised overnight?	155 (14.0%)	141 (13.0%)	104 (9.1%)	130 (13.4%)	44 (4.9%)
Was catheter removed?	156 (14.1%)	135 (12.4%)	105 (9.2%)	119 (12.3%)	47 (5.2%)
Did patient have interim haemodialysis?	170 (15.4%)	156 (14.3%)	132 (11.6%)	137 (14.1%)	42 (4.7%)
Did patient transfer to permanent haemodialysis?	165 (14.9%)	157 (14.4%)	129 (11.3%)	122 (12.6%)	49 (5.4%)

**Table 15 Transplant baseline data**

Variable	2016	2017	2018	2019	2020
Frequency	1257	1290	1317	1315	1072
Recipient CMV antibody status	124 (9.9%)	53 (4.1%)	4 (0.3%)	25 (1.9%)	54 (5.0%)
Recipient EBV antibody status	133 (10.6%)	51 (4.0%)	4 (0.3%)	27 (2.1%)	55 (5.1%)
Donor source	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor age	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor sex	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Total ischaemia (to nearest hour)	135 (10.7%)	60 (4.7%)	17 (1.3%)	83 (6.3%)	36 (3.4%)
Immediate function	117 (9.3%)	31 (2.4%)	13 (1.0%)	26 (2.0%)	18 (1.7%)
HLA-A mismatch	28 (2.2%)	23 (1.8%)	4 (0.3%)	11 (0.8%)	21 (2.0%)
HLA-B mismatch	28 (2.2%)	23 (1.8%)	4 (0.3%)	11 (0.8%)	21 (2.0%)
HLA-DR mismatch	28 (2.2%)	23 (1.8%)	4 (0.3%)	11 (0.8%)	21 (2.0%)
HLA-DQ mismatch	566 (45.0%)	537 (41.6%)	488 (37.1%)	197 (15.0%)	98 (9.1%)
Donor blood group	14 (1.1%)	1 (0.1%)	0 (0.0%)	0 (0.0%)	4 (0.4%)
Recipient blood group	8 (0.6%)	0 (0.0%)	1 (0.1%)	0 (0.0%)	3 (0.3%)
Recipient authorised match PRA from OrganMatch	87 (6.9%)	120 (9.3%)	241 (18.3%)	12 (0.9%)	21 (2.0%)

**Table 16 Cause of graft failure**

Variable	2016	2017	2018	2019	2020
Frequency	299	319	369	313	305
Cause of graft failure	11 (3.7%)	38 (11.9%)	25 (6.8%)	51 (16.3%)	15 (4.9%)

# ANZDATA Missing Data Report

**Table 17 Rejection data**

Variable	2016	2017	2018	2019	2020
Frequency	425	541	473	407	404
Was a biopsy performed?	3 (0.7%)	2 (0.4%)	2 (0.4%)	2 (0.5%)	0 (0.0%)
Response of this rejection to treatment	19 (4.5%)	40 (7.4%)	57 (12.1%)	26 (6.4%)	44 (10.9%)
Primary treatment of rejection	11 (2.6%)	10 (1.8%)	19 (4.0%)	2 (0.5%)	20 (5.0%)

**Table 18 Rejection data if biopsy performed**

Variable	2016	2017	2018	2019	2020
Frequency	409	529	462	400	398
If biopsy is Yes ?Cellular	10 (2.4%)	17 (3.2%)	23 (5.0%)	4 (1.0%)	323 (81.2%)
If biopsy is Yes ?Glomerular	14 (3.4%)	17 (3.2%)	20 (4.3%)	14 (3.5%)	322 (80.9%)
If biopsy is Yes ?Vascular	18 (4.4%)	24 (4.5%)	24 (5.2%)	12 (3.0%)	322 (80.9%)
Humoral Rejection	20 (4.9%)	17 (3.2%)	28 (6.1%)	28 (7.0%)	322 (80.9%)
If biopsy is Yes ?Antibody mediated	409 (100.0%)	529 (100.0%)	462 (100.0%)	400 (100.0%)	163 (41.0%)
If biopsy is Yes ?T-cell mediated	409 (100.0%)	529 (100.0%)	462 (100.0%)	400 (100.0%)	155 (38.9%)
If biopsy is Yes ?Presence of donor specific antibody(DSA)	409 (100.0%)	529 (100.0%)	462 (100.0%)	400 (100.0%)	330 (82.9%)
If biopsy is Yes and Banff g is known	60 (14.7%)	39 (7.4%)	35 (7.6%)	21 (5.3%)	40 (10.1%)
If biopsy is Yes and Banff i is known	55 (13.4%)	38 (7.2%)	35 (7.6%)	18 (4.5%)	36 (9.0%)
If biopsy is Yes and Banff t is known	55 (13.4%)	38 (7.2%)	33 (7.1%)	19 (4.8%)	33 (8.3%)
If biopsy is Yes and Banff v is known	62 (15.2%)	47 (8.9%)	39 (8.4%)	20 (5.0%)	44 (11.1%)
If biopsy is Yes and Banff ptc is known	402 (98.3%)	228 (43.1%)	135 (29.2%)	51 (12.8%)	46 (11.6%)
If biopsy is Yes and Banff c4d is known	409 (100.0%)	529 (100.0%)	462 (100.0%)	400 (100.0%)	198 (49.7%)
If biopsy is Yes and Banff cg is known	409 (100.0%)	529 (100.0%)	462 (100.0%)	400 (100.0%)	205 (51.5%)
If biopsy is Yes and Banff ci is known	409 (100.0%)	529 (100.0%)	462 (100.0%)	400 (100.0%)	217 (54.5%)
If biopsy is Yes and Banff ct is known	409 (100.0%)	529 (100.0%)	462 (100.0%)	400 (100.0%)	216 (54.3%)
If biopsy is Yes and Banff cv is known	409 (100.0%)	529 (100.0%)	462 (100.0%)	400 (100.0%)	216 (54.3%)
If biopsy is Yes and Banff mm is known	409 (100.0%)	529 (100.0%)	462 (100.0%)	400 (100.0%)	236 (59.3%)
If biopsy is Yes and Banff ah is known	409 (100.0%)	529 (100.0%)	462 (100.0%)	400 (100.0%)	202 (50.8%)
If biopsy is Yes and Banff ti is known	409 (100.0%)	529 (100.0%)	462 (100.0%)	400 (100.0%)	231 (58.0%)
If biopsy is Yes and Banff i-IFTA is known	409 (100.0%)	529 (100.0%)	462 (100.0%)	400 (100.0%)	247 (62.1%)

**Table 19 Rejection data if biopsy not performed**

Variable	2016	2017	2018	2019	2020
Frequency	13	10	9	5	6
Likelihood of rejection if biopsy not performed	1 (7.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)



# ANZDATA Missing Data Report



**Table 20 Transplant follow-up data, 0 months**

Variable	2016	2017	2018	2019	2020
Frequency	1282	1312	1345	1332	1073
Weight	136 (10.6%)	67 (5.1%)	59 (4.4%)	70 (5.3%)	66 (6.2%)
Drug data	121 (9.4%)	60 (4.6%)	64 (4.8%)	37 (2.8%)	21 (2.0%)

**Table 21 Transplant follow-up data, 1 months**

Variable	2016	2017	2018	2019	2020
Frequency	1268	1308	1326	1321	1042
Weight	138 (10.9%)	49 (3.7%)	47 (3.5%)	32 (2.4%)	53 (5.1%)
Serum creatinine	114 (9.0%)	45 (3.4%)	37 (2.8%)	24 (1.8%)	28 (2.7%)
Drug data	98 (7.7%)	33 (2.5%)	23 (1.7%)	24 (1.8%)	31 (3.0%)

**Table 22 Transplant follow-up data, 2 months**

Variable	2016	2017	2018	2019	2020
Frequency	1216	1314	1331	1318	1044
Weight	174 (14.3%)	87 (6.6%)	53 (4.0%)	56 (4.2%)	83 (8.0%)
Serum creatinine	130 (10.7%)	56 (4.3%)	34 (2.6%)	42 (3.2%)	50 (4.8%)
Drug data	114 (9.4%)	51 (3.9%)	21 (1.6%)	50 (3.8%)	57 (5.5%)

**Table 23 Transplant follow-up data, 3 months**

Variable	2016	2017	2018	2019	2020
Frequency	1193	1302	1307	1286	1081
Weight	170 (14.2%)	140 (10.8%)	81 (6.2%)	82 (6.4%)	90 (8.3%)
Serum creatinine	113 (9.5%)	85 (6.5%)	52 (4.0%)	62 (4.8%)	65 (6.0%)
Drug data	104 (8.7%)	79 (6.1%)	40 (3.1%)	66 (5.1%)	74 (6.8%)

**Table 24 Transplant follow-up data, 6 months**

Variable	2016	2017	2018	2019	2020
Frequency	1186	1275	1287	1292	1058
Weight	218 (18.4%)	197 (15.5%)	154 (12.0%)	157 (12.2%)	177 (16.7%)
Serum creatinine	138 (11.6%)	98 (7.7%)	108 (8.4%)	114 (8.8%)	127 (12.0%)
Drug data	134 (11.3%)	108 (8.5%)	98 (7.6%)	122 (9.4%)	137 (12.9%)

**Table 25 Transplant follow-up data, 12 months**

Variable	2016	2017	2018	2019	2020
Frequency	1050	1219	1258	1287	1272
Weight	177 (16.9%)	148 (12.1%)	154 (12.2%)	171 (13.3%)	224 (17.6%)
Serum creatinine	113 (10.8%)	84 (6.9%)	112 (8.9%)	117 (9.1%)	163 (12.8%)
Drug data	100 (9.5%)	81 (6.6%)	107 (8.5%)	116 (9.0%)	152 (11.9%)

# ANZDATA Missing Data Report



**Table 26 Transplant follow-up data, 24 months**

Variable	2016	2017	2018	2019	2020
Frequency	990	1018	1183	1227	1262
Weight	161 (16.3%)	132 (13.0%)	162 (13.7%)	179 (14.6%)	255 (20.2%)
Serum creatinine	86 (8.7%)	76 (7.5%)	116 (9.8%)	118 (9.6%)	164 (13.0%)
Drug data	82 (8.3%)	75 (7.4%)	113 (9.6%)	122 (9.9%)	177 (14.0%)

**Table 27 Transplant follow-up data, 36 months**

Variable	2016	2017	2018	2019	2020
Frequency	909	957	991	1150	1198
Weight	129 (14.2%)	148 (15.5%)	126 (12.7%)	176 (15.3%)	262 (21.9%)
Serum creatinine	79 (8.7%)	86 (9.0%)	84 (8.5%)	110 (9.6%)	190 (15.9%)
Drug data	75 (8.3%)	85 (8.9%)	87 (8.8%)	114 (9.9%)	193 (16.1%)

**Table 28 Transplant follow-up data, 60 months**

Variable	2016	2017	2018	2019	2020
Frequency	809	806	847	888	916
Weight	161 (19.9%)	132 (16.4%)	132 (15.6%)	159 (17.9%)	207 (22.6%)
Serum creatinine	99 (12.2%)	64 (7.9%)	93 (11.0%)	107 (12.0%)	133 (14.5%)
Drug data	89 (11.0%)	62 (7.7%)	94 (11.1%)	115 (13.0%)	142 (15.5%)

**Table 29 Transplant follow-up data, 84 months**

Variable	2016	2017	2018	2019	2020
Frequency	726	741	729	749	779
Weight	141 (19.4%)	122 (16.5%)	106 (14.5%)	135 (18.0%)	181 (23.2%)
Serum creatinine	88 (12.1%)	76 (10.3%)	80 (11.0%)	73 (9.7%)	125 (16.0%)
Drug data	73 (10.1%)	75 (10.1%)	82 (11.2%)	85 (11.3%)	129 (16.6%)

**Table 30 Transplant follow-up data, 120 months**

Variable	2016	2017	2018	2019	2020
Frequency	489	499	599	637	644
Weight	83 (17.0%)	75 (15.0%)	102 (17.0%)	105 (16.5%)	154 (23.9%)
Serum creatinine	46 (9.4%)	46 (9.2%)	66 (11.0%)	65 (10.2%)	101 (15.7%)
Drug data	38 (7.8%)	51 (10.2%)	69 (11.5%)	79 (12.4%)	108 (16.8%)

**Table 31 Transplant follow-up data, 180 months**

Variable	2016	2017	2018	2019	2020
Frequency	306	366	312	375	354
Weight	64 (20.9%)	48 (13.1%)	56 (17.9%)	71 (18.9%)	88 (24.9%)
Serum creatinine	42 (13.7%)	28 (7.7%)	37 (11.9%)	44 (11.7%)	56 (15.8%)
Drug data	40 (13.1%)	35 (9.6%)	39 (12.5%)	49 (13.1%)	68 (19.2%)

# ANZDATA Missing Data Report



**Table 32 Transplant follow-up data, 240 months**

Variable	2016	2017	2018	2019	2020
Frequency	184	197	185	201	220
Weight	31 (16.8%)	32 (16.2%)	33 (17.8%)	37 (18.4%)	55 (25.0%)
Serum creatinine	19 (10.3%)	22 (11.2%)	23 (12.4%)	24 (11.9%)	37 (16.8%)
Drug data	21 (11.4%)	24 (12.2%)	23 (12.4%)	27 (13.4%)	41 (18.6%)

**Table 33 Transplant follow-up data, 300 months**

Variable	2016	2017	2018	2019	2020
Frequency	96	94	77	96	109
Weight	16 (16.7%)	18 (19.1%)	16 (20.8%)	17 (17.7%)	29 (26.6%)
Serum creatinine	9 (9.4%)	11 (11.7%)	9 (11.7%)	8 (8.3%)	24 (22.0%)
Drug data	8 (8.3%)	15 (16.0%)	10 (13.0%)	10 (10.4%)	23 (21.1%)

**Table 34 Transplant follow-up data, 360 months**

Variable	2016	2017	2018	2019	2020
Frequency	46	44	54	54	50
Weight	10 (21.7%)	8 (18.2%)	10 (18.5%)	9 (16.7%)	11 (22.0%)
Serum creatinine	6 (13.0%)	7 (15.9%)	5 (9.3%)	5 (9.3%)	7 (14.0%)
Drug data	7 (15.2%)	3 (6.8%)	5 (9.3%)	7 (13.0%)	6 (12.0%)

**Table 35 Transplant follow-up data, 420 months**

Variable	2016	2017	2018	2019	2020
Frequency	30	28	20	24	29
Weight	10 (33.3%)	7 (25.0%)	6 (30.0%)	6 (25.0%)	9 (31.0%)
Serum creatinine	6 (20.0%)	4 (14.3%)	2 (10.0%)	4 (16.7%)	6 (20.7%)
Drug data	6 (20.0%)	4 (14.3%)	2 (10.0%)	6 (25.0%)	6 (20.7%)

**Table 36 Transplant follow-up data, 480 months**

Variable	2016	2017	2018	2019	2020
Frequency	9	15	15	15	13
Weight	1 (11.1%)	2 (13.3%)	4 (26.7%)	3 (20.0%)	3 (23.1%)
Serum creatinine	0 (0.0%)	1 (6.7%)	2 (13.3%)	2 (13.3%)	2 (15.4%)
Drug data	0 (0.0%)	0 (0.0%)	2 (13.3%)	2 (13.3%)	2 (15.4%)

**Table 37 Transplant follow-up data, 540 months**

Variable	2016	2017	2018	2019	2020
Frequency	6	0	2	4	4
Weight	2 (33.3%)	-	0 (0.0%)	1 (25.0%)	0 (0.0%)
Serum creatinine	2 (33.3%)	-	0 (0.0%)	0 (0.0%)	0 (0.0%)
Drug data	2 (33.3%)	-	0 (0.0%)	1 (25.0%)	0 (0.0%)

# ANZDATA Missing Data Report

**Table 38 Transplant follow-up data, 600 months**

Variable	2016	2017	2018	2019	2020
Frequency	0	0	0	0	0
Weight	-	-	-	-	-
Serum creatinine	-	-	-	-	-
Drug data	-	-	-	-	-

**Table 39 Paediatric assessment at entry**

Variable	2016	2017	2018	2019	2020
Frequency	40	48	45	32	32
Height	1 (2.5%)	1 (2.1%)	0 (0.0%)	1 (3.1%)	1 (3.1%)
Weight	1 (2.5%)	1 (2.1%)	0 (0.0%)	1 (3.1%)	0 (0.0%)
Paediatric Assessment at end of each Survey	2 (5.0%)	2 (4.2%)	0 (0.0%)	2 (6.3%)	1 (3.1%)

**Table 40 Paediatric assessment at survey**

Variable	2016	2017	2018	2019	2020
Frequency	340	351	360	355	354
Height	19 (5.6%)	21 (6.0%)	14 (3.9%)	18 (5.1%)	35 (9.9%)
Weight	17 (5.0%)	21 (6.0%)	14 (3.9%)	14 (3.9%)	34 (9.6%)
Paediatric Assessment at end of each Survey	19 (5.6%)	19 (5.4%)	13 (3.6%)	15 (4.2%)	28 (7.9%)

**Table 41 Parenthood data**

Variable	2016	2017	2018	2019	2020
Frequency	51	60	52	41	48
Pregnancy outcome	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Neonatal survival	12 (23.5%)	9 (15.0%)	9 (17.3%)	4 (9.8%)	8 (16.7%)
Gestational age (best clinical estimate, weeks)	50 (98.0%)	37 (61.7%)	15 (28.8%)	7 (17.1%)	3 (6.3%)
Diabetes	50 (98.0%)	30 (50.0%)	20 (38.5%)	18 (43.9%)	29 (60.4%)
Hypertension (Somanz 2014 definition)	50 (98.0%)	33 (55.0%)	28 (53.8%)	21 (51.2%)	26 (54.2%)
CYA Immunosuppression at conception	50 (98.0%)	36 (60.0%)	25 (48.1%)	7 (17.1%)	5 (10.4%)
AZA Immunosuppression at conception	50 (98.0%)	34 (56.7%)	22 (42.3%)	6 (14.6%)	5 (10.4%)
Pred Immunosuppression at conception	49 (96.1%)	34 (56.7%)	22 (42.3%)	6 (14.6%)	5 (10.4%)
Tac Immunosuppression at conception	49 (96.1%)	33 (55.0%)	23 (44.2%)	6 (14.6%)	5 (10.4%)
MMF Immunosuppression at conception	49 (96.1%)	35 (58.3%)	26 (50.0%)	7 (17.1%)	5 (10.4%)
Sirol Immunosuppression at conception	50 (98.0%)	36 (60.0%)	27 (51.9%)	8 (19.5%)	5 (10.4%)
Other Immunosuppression at conception	50 (98.0%)	38 (63.3%)	29 (55.8%)	8 (19.5%)	5 (10.4%)
Labour type	49 (96.1%)	38 (63.3%)	27 (51.9%)	22 (53.7%)	25 (52.1%)
Delivery type	50 (98.0%)	38 (63.3%)	27 (51.9%)	21 (51.2%)	26 (54.2%)
Congenital condition present?	49 (96.1%)	35 (58.3%)	18 (34.6%)	4 (9.8%)	5 (10.4%)

# ANZDATA Missing Data Report



**Table 42 Parenthood birthweight data**

Variable	2016	2017	2018	2019	2020
Frequency	42	55	48	38	44
Weight at birth (gms)	7 (16.7%)	11 (20.0%)	9 (18.8%)	5 (13.2%)	5 (11.4%)

**Table 43 Parenthood creatinine prior to conception**

Variable	2016	2017	2018	2019	2020
Frequency	16	19	14	11	16
Creatinine prior to conception (umol/L)	2 (12.5%)	3 (15.8%)	1 (7.1%)	0 (0.0%)	0 (0.0%)

**Table 44 Parenthood creatinine post delivery**

Variable	2016	2017	2018	2019	2020
Frequency	16	19	14	11	10
Creatinine 3 months post delivery (umol/L)	2 (12.5%)	5 (26.3%)	2 (14.3%)	2 (18.2%)	2 (20.0%)

**Table 45 Non-skin cancer data**

Variable	2016	2017	2018	2019	2020
Frequency	676	626	650	612	501
Cancer type	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Primary site of cancer category	15 (2.2%)	12 (1.9%)	30 (4.6%)	21 (3.4%)	19 (3.8%)
Cancer staging code	43 (6.4%)	52 (8.3%)	79 (12.2%)	70 (11.4%)	47 (9.4%)
Type 1st treatment	45 (6.7%)	50 (8.0%)	74 (11.4%)	69 (11.3%)	60 (12.0%)